BRIEF-Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing And Amendment To Existing Convertible Note

BY Reuters | CORPORATE | 03/16/26 08:20 AM EDT

March 16 (Reuters) - Outlook Therapeutics Inc (OTLK):

* OUTLOOK THERAPEUTICS ANNOUNCES NEW $18.4 MILLION NON-CONVERTIBLE NOTE FINANCING AND AMENDMENT TO EXISTING CONVERTIBLE NOTE

* OUTLOOK THERAPEUTICS INC (OTLK) - EXTENDS MATURITY DATE OF EXISTING CONVERTIBLE NOTE TO DECEMBER 31, 2026

* OUTLOOK THERAPEUTICS INC (OTLK) - LENDER CONFIRMS EXISTING NOTE IS NOT IN DEFAULT

* OUTLOOK THERAPEUTICS INC (OTLK) - ENTERS $18.4 MILLION NEW NOTE, EXPECTS $17 MILLION NET PROCEEDS

* OUTLOOK THERAPEUTICS INC (OTLK) - PROCEEDS FROM NEW NOTE TO PAY DOWN EXISTING NOTE, $10.8 MILLION PRINCIPAL AND INTEREST REMAINING ON EXISTING NOTE Source text: Further company coverage:

In general the bond market is volatile, and fixed income securities carry interest rate risk. (As interest rates rise, bond prices usually fall, and vice versa. This effect is usually more pronounced for longer-term securities.) Fixed income securities also carry inflation risk and credit and default risks for both issuers and counterparties. Unlike individual bonds, most bond funds do not have a maturity date, so avoiding losses caused by price volatility by holding them until maturity is not possible.

Lower-quality debt securities generally offer higher yields, but also involve greater risk of default or price changes due to potential changes in the credit quality of the issuer. Any fixed income security sold or redeemed prior to maturity may be subject to loss.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.

fir_news_article